Pharma Industry News
Printable Version   Email to a friend

Strategic Planning for Discovery, Development and Clinical Operations in China, India and other Emerging Regions

NEEDHAM, Mass. -- February 6, 2006 -- The Pharmaceutical Strategy Series (PSS), a division of Cambridge Healthtech Institute, posted details for its Global R&D Congress, May 15-16, 2007, Park Hyatt Hotel in Philadelphia, PA. Speakers and delegates from PSS’s annual China and India conferences, as well as those involved in projects in Asia, Russia, Eastern Europe and Latin America, will discuss the opportunities and challenges of drug discovery and development in emerging regions. The event website is www.healthtech.com/2007/PCG.

“We are extremely pleased to present this conference to the industry,” said Micah Lieberman, Conference Director for the Pharmaceutical Strategy Series and conference chairperson. “PSS conducted months of research and interviews with R&D executives; and based on our findings, we’ve developed a comprehensive event for bio/pharmaceutical companies to successfully expand and/or develop their R&D operations overseas. Basic research and discovery, preclinical development, and clinical operations will be carefully reviewed so our delegates’ companies can start reaping the full benefits of outsourcing R&D in Asia and other Emerging Regions.”

 

The Global R&D Congress brings together an impressive roster of senior executive speakers representing US FDA, Merck, Wyeth, Pfizer, Roche, NIH, Biogen Idec, Bristol-Myers Squibb, Johnson & Johnson, to name a few, who will participate in case studies and panel discussions. Participants will attend a complimentary pre-conference tutorial, Planning a Global Strategy Around Intellectual Property Law: IP Barriers, and Trends, to be lead by Greg Kalbaugh, US-India Business Council and Mak Jawadekar, Ph.D., Pfizer.

 

More on the Global R&D Congress can be found at www.healthtech.com/2007/PCG.

 

About the Pharmaceutical Strategy Series
The Pharmaceutical Strategy Series (PSS) is a division of Cambridge Healthtech Institute. PSS programs have been designed to help the R&D leaders and corporate executives assess business opportunities, enhance corporate value and forecast the economic and regulatory landscape within the rapidly changing pharmaceutical & biotechnology industries. PSS chooses the most topical issues to cover, based largely on advice given by the PSS Advisory Board. The Advisory Board is comprised of decision-makers at most of the world's leading pharmaceutical companies. Presentations in each Executive Forum will give you the ideas, information, and resources you need to make faster and smarter decisions. www.pharmaseries.com

 

About Cambridge Healthtech Institute

Cambridge Healthtech Institute’s renowned conferences are the underpinning for all our other information resources. Each year, CHI organizes over 80 conferences held throughout the US, including the Molecular Medicine Tri-Conference, Beyond Genome, PepTalk: The Protein Information Week, World Pharmaceutical Congress and the newly acquired Bio-IT World Conference & Expo. The company strives to develop quality programs that provide valuable new insights and competing points of view while offering balanced coverage of the latest developments. Basic research related to commercial implications is covered, with heavy emphasis placed on end-user insights into new products and technology as well as coverage on the strategy behind the business. Leading researchers and business experts from top pharmaceutical, biotech and academic organizations present their most current findings in a forum that features panel discussions and audience participation. Over the past 14 years, CHI has produced more than 600 conferences, attracting more than 50,000 attendees from around the world.  www.healthtech.com

 

Contact information

Speaker and content inquiries:

Micah Lieberman, Conference Director, at mlieberman@pharmaseries.com

 

Sponsor and partnership inquiries:

Laura Ames, Manager, Business Development, at lames@healthtech.com

 

Media inquiries:

Lisa Scimemi, Senior Marketing Manager, at lscimemi@healthtech.com


Lisa Scimemi

Cambridge Healthtech Institute

781-972-5419

lscimemi@healthtech.com

Latest Pharma Industry News...

Pharma Industry News Archive

2008: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct
2007: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2006: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2005: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2004: Jan | Feb | Mar | Apr | May | Jul | Aug | Sep | Oct | Nov | Dec
2003: Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec
2002: Jan | Apr | May | Jun | Aug | Sep | Oct | Nov | Dec

More News Resources


MedNotes
Latest FDA Drug Alerts
October 9, 2008
Audience: Pediatric and primary healthcare professionals, consumers [Posted 10/09/2008] FDA notified healthcare professionals and...
October 7, 2008
Audience: Pulmonary care health professionals and patients[UPDATE 10/07/2008] FDA informed healthcare professionals that FDA has...
October 3, 2008
Audience: Healthcare professionals, consumers [Posted 10/03/2008] FDA notified healthcare professionals of a Class I Recall of...
October 2, 2008
Audience: Physical medicine and rehabilitation specialists, anesthesia healthcare professionals, hospital surgical service...
More...
Latest Drug Information Updates

Cinryze
Cinryze is a C1-esterase inhibitor indicated for routine prophylaxis against angioedema attacks in adolescent and adult patients with Hereditary Angioedema (HAE).

Akten
Akten (lidocaine hydrochloride) Ophthalmic Gel is a topical, ocular anesthetic formulation for use in ocular procedures that require a topical anesthetic agent.

AdreView
AdreView is a diagnostic radiopharmaceutical agent indicated for use in the detection of rare neuroendocrine tumors in children and adults.

Sancuso
Sancuso (granisetron transdermal system) is an anti-emetic transdermal delivery system indicated for the control of nausea and vomiting in patients receiving moderately and/or highly nausea-inducing chemotherapy.

Nplate
Nplate (romiplostim) is a thrombopoietin mimetic peptibody for the treatment of thrombocytopenia in adult patients with chronic immune (idiopathic) thrombocytopenic purpura (ITP).

Xenazine
Xenazine (tetrabenazine) is a selective and reversible centrally-acting dopamine depleting drug indicated for the treatment of chorea associated with Huntington's disease.

Cleviprex
Cleviprex is an intravenous, ultrashort-acting calcium channel blocker under development for the treatment of severely elevated blood pressure in the hospital setting when oral therapy is not feasible or desirable.

Stavzor
Stavzor is delayed-release valproic acid formulated in the EnteriCare enteric soft gelatin capsule delivery system designed to minimize GI adverse events. Stavzor is indicated for the treatment of manic episodes associated with bipolar disorder, adjunctive therapy in multiple seizure types (including epilepsy), and prophylaxis of migraine headaches.

Navstel
Navstel is a balanced salt ophthalmic solution for use as an intraocular irrigation during surgical procedures involving perfusion of the eye.

Eovist
Eovist (gadoxetate disodium) is a gadolinium-based contrast agent for intravenous use in T1-weighted magnetic resonance imaging (MRI) of the liver to detect and characterize lesions in adults with known or suspected focal liver disease.

Evolence
Evolence is a collagen-based structural dermal filler for the correction of moderate to deep facial wrinkles and folds, such as nasolabial folds.

Kinrix
Kinrix [Diphtheria and Tetanus Toxoids and Acellular Pertussis Adsorbed and Inactivated Poliovirus Vaccine] is a combination vaccine for protection against diphtheria, tetanus, pertussis and polio diseases in children.

Durezol
Durezol (difluprednate ophthalmic emulsion) is a topical steroid for the treatment of postoperative ocular inflammation and pain.

PrandiMet
PrandiMet (repaglinide and metformin HCl) is a fixed-dose combination of the fast-acting secretagogue replaglinide (also known as Prandin) and insulin sensitizer, metformin, indicated for the treatment of type 2 diabetes.

Pentacel
Pentacel is a combination vaccine indicated for active immunization against diphtheria, tetanus, pertussis, poliomyelitis and invasive disease due to Haemophilus influenzae type b in children 6 weeks through 4 years of age.

More...